Core Viewpoint - Encompass Health (EHC) is positioned well to continue its trend of beating earnings estimates, supported by a strong history of performance in the Zacks Medical - Outpatient and Home Healthcare industry [1] Group 1: Earnings Performance - Encompass Health has consistently surpassed earnings estimates, achieving an average beat of 15.17% over the last two quarters [1] - In the most recent quarter, the company reported earnings of $1.11 per share against an expectation of $1.01, resulting in a surprise of 9.90% [1] - For the previous quarter, the consensus estimate was $0.93 per share, while the actual earnings were $1.12, leading to a surprise of 20.43% [1] Group 2: Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Encompass Health, with a positive Zacks Earnings ESP indicating a strong likelihood of an earnings beat [2] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced a positive surprise nearly 70% of the time [2] - Encompass Health currently has an Earnings ESP of +0.13%, suggesting analysts are optimistic about the company's earnings prospects [3] Group 3: Upcoming Earnings Report - The next earnings report for Encompass Health is expected to be released on October 28, 2024 [3]

Encompass Health (EHC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Individual investo ...

Encompass Health Corporation (EHC) has been gaining on growing patient admissions, commendable expansion initiatives and a robust cash position. A solid 2024 business outlook also reinforces investors' confidence in the stock. EHC's Zacks Rank & Price Performance Encompass Health currently carries a Zacks Rank #3 (Hold). The stock has gained 43.4% in the past year compared with the industry's 34.5% growth. The Zacks Medical sector has rallied 13.1% and the S&P 500 composite increased 33.4% in the same time ...

Encompass Health Rehabilitation Hospital of Fort Mill provides essential rehabilitative services that help patients recovering from strokes, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions regain function and independence. Patients receive a minimum of three hours of intensive therapy for five days each week, frequent physician visits and 24-hour nursing care. "The need for inpatient rehabilitative care in the Fort Mill and greater Charlotte area has been growing rapidly" ...

Encompass Health Corporation (EHC) shares have shot up 39.4% in the year-to-date period, outperforming the industry's return of 17.9% and the S&P 500 Index's rise of 18.4%. Growing patient volumes and impressive growth-related initiatives appear to have catalyzed this bullishness. Currently priced at $93.05, the stock is just 1.4% below its 52-week high of $94.38. This proximity underscores investor confidence and market optimism about this healthcare company's prospects. It has the ingredients for further ...

Core Viewpoint - Encompass Health (EHC) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive earnings outlook that may lead to increased stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with stock price movements [4][6]. - Rising earnings estimates for Encompass Health suggest an improvement in the company's underlying business, likely resulting in higher stock prices [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2024, Encompass Health is expected to earn $4.16 per share, reflecting a 14.3% increase from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Encompass Health has increased by 1.5% [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - Encompass Health's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns [10].

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share EHC New York Stock Exchange FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0 ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------|-------|------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2024 Second Quarter Earnings Call | | | | | | | | August 6, 2024 | | Supplemental information | | | | | | | | | | | | | | | | | | | | | | | | | | | Forward-looking statements The information contained in this presentation includes certain estimates, projecti ...

Encompass Health Corporation (NYSE:EHC) Q2 2024 Earnings Call August 6, 2024 10:00 AM ET Company Participants Mark Miller - Chief Investor Relations Officer Mark Tarr - President and Chief Executive Officer Doug Coltharp - Executive Vice President and Chief Financial Officer Conference Call Participants Whit Mayo - Leerink Partners A.J. Rice - UBS Andrew Mok - Barclays Pito Chickering - Deutsche Bank Kevin Fischbeck - Bank of America Scott Fidel - Stephens Brian Tanquilut - Jefferies Jared Haase - William B ...